• For investors wondering whether Moderna at around US$53.72 is a bargain or a value trap, this article walks through what the current price might be implying about the stock.
• The share price has moved 6.0% over the past week and 4.6% over the past month. The year to date return sits at 74.1% and the 1 year return at 113.8%, contrasted with a 61.1% decline over 3 years and a 69.8% decline over 5 years.
• These mixed return figures have kept Moderna in focus as investors weigh recent company updates against a longer period of weaker returns. The aim here is to put those moves into context by looking at how different valuation methods line up with the current price.
• Right now, Moderna has a valuation score of 1 out of 6. The next sections will compare what various models say about fair value, then conclude with a broader way to think about valuation that goes beyond the numbers alone.

Moderna scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Moderna Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows, discounts them back to today using a required return, and sums them to estimate what the business might be worth per share right now.

For Moderna, the latest twelve month free cash flow (FCF) is a loss of about US$2.19b. Analyst and extrapolated projections used in this 2 Stage Free Cash Flow to Equity model show FCF remaining negative through 2029, then turning positive to US$254 million in 2030, with further positive figures extrapolated for the following years. These later years are based on Simply Wall St estimates once analyst inputs run out.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about US$26.27 per share. Compared with the recent share price around US$53.72, the model implies Moderna is about 104.5% overvalued on this DCF view.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Moderna may be overvalued by 104.5%. Discover 60 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Moderna Price vs Sales

For companies where earnings are volatile or negative, the P/S ratio is often a practical yardstick because it relates the share price to revenue, which tends to be more stable than profits.

Growth expectations and risk still matter here. Investors usually accept a higher P/S ratio when they expect stronger future growth or see lower risk, and look for a lower P/S when growth is uncertain or risks are higher.

Moderna currently trades on a P/S of about 11x. This sits close to the Biotechs industry average P/S of around 12x and above the peer group average of about 5.6x. On the surface, that puts the stock on a richer multiple than many peers, while broadly in line with the wider industry.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/S might be reasonable for Moderna, given factors such as earnings growth, industry, profit margin, market cap and company specific risks. Because it blends these elements, it can give a more tailored view than a simple comparison with peers or an industry average.

Moderna’s Fair Ratio is about 1.32x, well below the current P/S of roughly 11x, which suggests the shares look overvalued on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Moderna Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Moderna, translate it into assumptions for future revenue, earnings and margins, and connect that to a Fair Value you can compare with the current price. This all happens within Simply Wall St’s Community page, where Narratives update automatically as news or earnings arrive. One investor might build a bullish Moderna Narrative around a Fair Value of about US$175.00, while another builds a cautious one around roughly US$12.00. Yet both can see how their story, forecast and valuation line up, so they can decide for themselves whether the price looks high or low against their own view, rather than relying only on standard ratios or a single model.

For Moderna however we will make it really easy for you with previews of two leading Moderna Narratives:

Each one links the same share price to a very different story, so your job is to decide which feels closer to how you see the business and its risks.

Fair Value: about US$175.00 per share

Implied undervaluation vs US$53.72: roughly 69.3%

Revenue growth used in this narrative: 48.43%

• Sees Moderna as having reinvested its COVID era windfall into a broad R&D pipeline while keeping the balance sheet relatively clean.
• Highlights that the company has been trading below book value, with many programs already funded and progressing through trials.
• Frames the past share price pullback as an overreaction and views Moderna as a comparatively lower risk biotech with multiple potential pipeline upsides.

Fair Value: about US$38.80 per share

Implied overvaluation vs US$53.72: roughly 38.4%

Revenue growth used in this narrative: 11.47%

• Accepts that the broader mRNA pipeline is expanding, but stresses that future growth is tied to execution on new products in infectious disease and oncology.
• Points out that the analyst case requires meaningful improvement in margins and a relatively high future P/E to support the fair value, with revenue and earnings forecasts spread across a wide range.
• Flags risks around slower COVID and respiratory vaccine demand, competition, cost cuts, regulatory pressure, funding needs for late stage assets, and the possibility that long term earnings and valuation fall short of optimistic scenarios.

Together, these two narratives bracket a wide range of potential fair values, from around US$38.80 up to about US$175.00, and show how much depends on your view of Moderna's pipeline, margins, and long run vaccine demand.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Moderna on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.